Engineered Chagasin Carriers Deliver Proteases to Cancer Cells, Inducing Antiproliferative Effects

Current cancer therapy often employs cytotoxic enzymes, but their systemic administration in activated forms poses significant safety risks due to off-target effects. A critical gap exists in developing delivery systems that can ensure site-selective activity, thereby improving the therapeutic index and reducing systemic toxicity. This research addresses the need for cancer-responsive elements that can precisely control the release of potent therapeutic agents, leveraging the specificity of peptide targeting sequences to enhance localized drug action.

Researchers engineered chagasin, a known protease inhibitor protein, to function as a targeted carrier. This involved integrating 11 distinct peptide targeting sequences into the chagasin structure, designed to bind specifically to receptors on cancer cells. The modified chagasin was then complexed with relevant cytotoxic proteases, specifically papain and bromelain, to form protease-bound chagasin complexes. The study's primary objective was to evaluate the ability of these complexes to achieve cancer-targeted release of the proteases and to assess their subsequent antiproliferative effects against various targeted cancer cell lines, establishing a proof-of-concept for this novel delivery system.

The study successfully demonstrated the functional efficacy of the engineered chagasin carriers. These carriers, equipped with 11 distinct peptide targeting sequences, effectively shuttled their protease cargo, papain and bromelain, towards specific cancer cell lines. A key finding was the confirmation that upon binding to their designated receptors on the cancer cell surface, the structural integrity of the chagasin carrier was indeed compromised. This engineered vulnerability led to the precise, localized release of the cytotoxic proteases, concentrating their activity at the intended site. This mechanism is crucial for enhancing the safety profile of cytotoxic enzyme therapies by minimizing off-target activity. > The protease-bound chagasin complexes exhibited clear antiproliferative effects against the targeted cancer cell lines, providing a robust proof-of-concept for this site-selective delivery and activation strategy. The research qualitatively established that the localized release of papain and bromelain was sufficient to induce a cytotoxic response, validating the design principle for cancer-specific protease delivery.